Two-Year Cohort Study of SARS-CoV-2, Verona, Italy, 2020‒2022.
Zeno Bisoffi, Nicoletta De Santis, Chiara Piubelli, Michela Deiana, Francesca Perandin, Pietro Girardi, Luca Heller, Natalia Alba, Carlo Pomari, Massimo Guerriero
中文译文
English
We performed a follow-up of a previously reported SARS-CoV-2 prevalence study (April‒May 2020) in Verona, Italy. Through May 2022, only <1.1% of the city population had never been infected or vaccinated; 8.8% was the officially reported percentage. Limiting protection measures and vaccination boosters to elderly and frail persons seems justified.
N Engl J Med. 2022 Mar 31;386(13):1288-1290
[PMID: 35139269 ]
Lancet. 2022 Mar 5;399(10328):924-944
[PMID: 35202601 ]
Proc Natl Acad Sci U S A. 2021 Aug 3;118(31):
[PMID: 34312227 ]
BMC Infect Dis. 2021 Oct 28;21(1):1111
[PMID: 34711190 ]
Crit Care Explor. 2022 Mar 28;4(4):e0673
[PMID: 35372848 ]
Euro Surveill. 2022 Apr;27(16):
[PMID: 35451363 ]
Sci Rep. 2021 Dec 1;11(1):23247
[PMID: 34853349 ]
Epidemiol Infect. 2021 Aug 03;149:e194
[PMID: 34645534 ]
N Engl J Med. 2022 May 12;386(19):1804-1816
[PMID: 35263534 ]
Emerg Infect Dis. 2021 Jan;27(1):
[PMID: 33261716 ]
J Infect Dis. 2022 Feb 1;225(3):396-403
[PMID: 34662409 ]
N Engl J Med. 2022 Jun 9;386(23):2201-2212
[PMID: 35613036 ]
Lancet Infect Dis. 2022 Jun;22(6):781-790
[PMID: 35366962 ]
JAMA Netw Open. 2021 Jan 4;4(1):e2033706
[PMID: 33399860 ]
Humans
Aged
SARS-CoV-2
COVID-19
Cohort Studies
Italy
Cross-Sectional Studies